Dieta Health

What Dieta Health does

Dieta Health is a Los Angeles-based digital health company (founded 2018/2019) that has built an AI-driven gastrointestinal platform centered on proprietary stool image recognition technology. The company's products include a consumer mobile app (iOS/Android) for tracking stool, food, medications, and symptoms; a clinician web portal for monitoring patient data; an admin portal for clinical-trial management; and a patient telemedicine service connecting users with gastroenterologists, dietitians, and coaches. Its core technology is a proprietary computer-vision AI that classifies stool images into five objective characteristics (Bristol Scale, consistency, fragmentation, fuzziness, and volume), validated in peer-reviewed clinical trials at Cedars-Sinai Medical Center, Mayo Clinic, and the Veterans Health Administration, and published in the American Journal of Gastroenterology and Crohn's & Colitis 360.

The business operates across four revenue streams: a freemium consumer app; enterprise licensing to pharmaceutical companies for GI clinical-trial data collection; white-label/OEM deployments for consumer health brands (e.g., the Metamucil App Powered by Dieta, built for Procter & Gamble); and a telemedicine service distributed through employers and direct-to-patient. Customers span individual IBS/IBD patients, gastroenterology clinicians, pharmaceutical sponsors, employers, and consumer-health brands. Dieta is privately held and backed by Techstars, UnitedHealthcare, Cedars-Sinai, Heron Rock Fund, and Verissimo Ventures, with ~$1.9M in disclosed pre-seed funding and a team of 1–10 employees. The company is HIPAA and GDPR compliant and operates its platform on AWS with SSL-encrypted data transit.

Name

Dieta Health

Legal name

Dieta Inc.

Website

https://dietahealth.com

Company type

Private

Founded year

2019

Operating status

Operating

Headcount range

1–10 employees

Short description

Dieta Health is a Los Angeles-based digital health company whose proprietary stool image recognition AI powers a mobile app, clinician portal, and enterprise platform for GI monitoring. It serves IBS/IBD patients, clinicians, pharmaceutical trial sponsors, and consumer health brands via white-label partnerships.

Ownership category

akta.pro rank

Product category

Gastroenterology Digital Health Platform

akta.pro primary industry

Gut Health & Digestive Nutrition (IBS, GERD, Elimination Diets) (HSADAFAH)

Keywords

• Digestive health platform
• AI stool analysis
• Gastroenterology software
• Clinical trial data
• IBS management tools

Headquarters

HQ city

Los Angeles

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Software

Cost components

Personnel, Technology or R&D, Marketing or Sales, Infrastructure, Operations

Revenue model

1. Consumer App (Freemium): Free mobile app for iOS and Android enables broad patient acquisition. Core stool tracking and basic features are free; premium telemedicine services (gastroenterologists, dietitians, coaches) are offered as a paid add-on delivered through employers and direct-to-patient.
2. Pharma / Clinical Trial Services: Dieta licenses its platform to pharmaceutical companies conducting GI clinical trials. The platform provides objective stool data collection, replacing subjective patient-reported outcomes. Revenue is derived from platform licensing, customization, and data services.
3. White-Label / OEM Licensing: Dieta white-labels its platform for consumer health brands, as demonstrated by the Metamucil App for Procter & Gamble. Revenue comes from licensing fees, customization, and ongoing platform fees.
4. Telemedicine / Direct Patient Care: Dieta launched a patient telemedicine service delivered through employers and direct-to-patient, connecting patients with gastroenterologists, dietitians, and coaches who use Dieta's portal and AI for personalized care.

Pricing tiers

Go-to-market motion3 records

Distribution channels5 records

Marketing channels7 records

Core offering

Dieta Health provides an AI-powered gastroenterology platform combining a patient-facing mobile app (iOS/Android) with a clinician web portal and a pharma-facing admin portal. Its proprietary stool image recognition AI classifies stool photos into five objective characteristics (Bristol Scale, consistency, fragmentation, fuzziness, volume), replacing subjective self-reporting with clinically validated measurement. The company also sells white-label deployments to consumer health brands and delivers a telemedicine service through employers and direct-to-patient.

Product overview

Dieta Health offers a unified gastroenterology digital health platform centered on its proprietary stool image recognition AI technology. The core offering consists of the Dieta Mobile App (iOS/Android) for patient tracking and the Dieta Web Portal for clinician monitoring, connected through an Admin Portal for pharmaceutical clinical trials. The platform's flagship stool image recognition AI classifies 5 objective stool characteristics from photos, providing clinical-grade analysis that surpasses patient self-reporting. Additional products include a telemedicine service connecting patients with gastroenterologists, dietitians, and coaches; a white-label Metamucil companion app built for Procter & Gamble; and a self-experiments feature for structured treatment optimization. The platform is clinically validated at Cedars-Sinai with peer-reviewed publications in the American Journal of Gastroenterology and has been expanded to support IBD, cirrhosis, and hepatic encephalopathy management.

Differentiator

Problem solved

Functional benefit

Products and services

• Dieta Mobile App Free iOS and Android mobile application for patients to capture stool images, food photos, medications, symptoms, and lifestyle factors. Proprietary AI performs stool image recognition across five objective characteristics (Bristol Scale, consistency, fragmentation, fuzziness, volume) and food image recognition for automatic labeling. Used by IBS, IBD, and other digestive disorder patients for self-tracking and self-experimentation.
• Dieta Web Portal (Clinician Portal)

Quantifiable outcome

• AI sensitivity 83% and specificity 94% vs patient self-reporting at 55% sensitivity and 71% specificity in classifying stool
• +5 more outcomes

Named customers4 records

Segments4 records

Ideal customer profiles5 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability8 records

Feature5 records

Partnerships

Four partnerships are on record, tiered core and minor.

• Procter & Gamble (P&G)coreOEM/ Whitelabel/ Licensing PartnerDieta created the 'Metamucil App Powered by Dieta' for Procter & Gamble's Metamucil fiber supplement. The white-labeled app helps users track digestive health, find optimal Metamucil dosage, and analyze results. This demonstrates Dieta's ability to customize and white-label its platform for major consumer health brands.
• Mayo CliniccoreStrategic or Co-development PartnerMayo Clinic collaborated with Dieta on a clinical study (42 subjects) published in the American Journal of Gastroenterology, demonstrating Dieta's AI app effectiveness in assisting cirrhosis patients with lactulose titration, improving Bristol Stool Scale goal achievement from 68% to 74%.
• Veterans Health Administration (VA) & Virginia Commonwealth University (VCU)coreStrategic or Co-development PartnerVA and VCU collaborated with Dieta on a clinical study (61 subjects approached, 46 completed) on cirrhosis and hepatic encephalopathy, published in AJG. The study showed significant improvement in lactulose self-management using Dieta's AI-BSS tool.
• Arena PharmaceuticalsminorGTM or Marketing PartnerDieta won second place in Arena Pharmaceuticals' innovation challenge. Arena was subsequently acquired by Pfizer, and Dieta was subsequently invited to present at Pfizer's headquarters in New York City.

Scale indicators9 records

Recent moves7 records

Expansion highlights5 records

Direct peers

• Vivante Health: Vivante Health provides a digestive health digital platform (GIThrive) combining app-based tracking, personalized nutrition, and on-demand coaching for employers and payers. Highly comparable to Dieta's consumer app and employer telemedicine channels, with overlapping focus on IBS and digestive conditions.
• Oshi Health: Oshi Health is a virtual-first gastroenterology care platform offering telehealth visits with GI specialists, dietitians, and behavioral health providers for conditions including IBS and IBD. Directly comparable to Dieta because it serves the same patient population, sells into employers and payers, and combines digital tools with clinician-led care.
• Ayble Health: Ayble Health is a digital digestive health platform offering personalized food, symptom, and microbiome tracking for IBS and IBD patients via a mobile app. Directly competes with Dieta on consumer-side digestive tracking, AI-driven food recommendations, and chronic condition management.
• Mahana Therapeutics: Mahana Therapeutics develops FDA-cleared prescription digital therapeutics for IBS, including Parallel, a CBT-based program. Comparable to Dieta as a digital-first IBS treatment sold through providers, health systems, and payers.
• Bold Health (Trellus Health): Trellus Health (formerly Bold Health) provides a digital digestive health platform combining AI-driven personalization, clinician access, and behavioral health for IBD and IBS patients. Directly comparable to Dieta on AI personalization, condition management focus, and employer/payer distribution.
• GI OnDEMAND: GI OnDEMAND is a gastroenterology-focused telehealth and digital care platform developed by the American College of Gastroenterology. Comparable to Dieta because it distributes GI-specialist virtual care to patients and employers through a digital platform, though it leans more on clinician delivery than AI.

Others

• Evidation Health: Evidation Health operates a health data platform that aggregates patient-generated health data for research and outcomes measurement. Comparable to Dieta in its use of consumer-generated health data for clinical research, though Evidation is a broader data platform and not a GI-specialized competitor.

Broad incumbents

• Teladoc Health: Teladoc Health is the largest U.S. virtual care provider offering general telehealth across many specialties, including chronic condition management for digestive health through employer and payer contracts. A broad incumbent whose generalist virtual care platform competes with Dieta's specialized GI telemedicine offering at the employer/payer level.

Emerging players

• Cara Care: Cara Care is a digestive health mobile app offering symptom and food tracking, personalized recommendations, and clinician content for IBS and related conditions, primarily in Europe. Comparable to Dieta on consumer-facing AI-driven digestive tracking and personalization, though primarily regional.
• metaMe Health: metaMe Health develops digital therapeutics for gastrointestinal conditions including IBS, using behavioral and digital interventions. Comparable to Dieta's mission to deliver non-drug, data-driven digestive care, though metaMe's modality is more CBT-based than AI-vision-based.

Market position

Strengths1 record

Weaknesses1 record

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

• Xx.com/DietaHealth
• LinkedInlinkedin.com/company/35577003
• Instagraminstagram.com/asafkraus
• Facebookfacebook.com/dietascience

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds5 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Dieta Health